Registration is now open for ResearchCon 2025, a free event the Cystic Fibrosis Foundation assembles each year for…
Articles by Margarida Maia, PhD
Trikafta (elexacaftor/tezacaftor/ivacaftor) improves lung function and nutrition status in adults and adolescents with cystic fibrosis (CF), and appears…
In people with cystic fibrosis (CF) — particularly those with pancreatic insufficiency, which affects digestion — constipation typically led…
Despite often using a contraceptive at some point, unintended pregnancy remains fairly common among women with cystic fibrosis (CF)…
Kaftrio, a combination of elexacaftor, tezacaftor, and ivacaftor that’s marketed as Trikafta in the U.S., may ease breathing and…
Starting treatment with the CFTR modulator Orkambi (lumacaftor/ivacaftor) early in life may provide long-term benefits for children with…
After one year of treatment with Kaftrio, a triple combination of elexacaftor, tezacaftor, and ivacaftor marketed as Trikafta in…
Dosing has begun in a Phase 2 clinical study testing ARCT-032, an experimental inhaled treatment Arcturus Therapeutics is developing…
Acceptance and commitment therapy (ACT), which helps people accept feelings and adjust behavior, was better than supportive psychotherapy for adults…
Rostra Therapeutics has launched a research project with the support of funding from the Cystic Fibrosis Antimicrobial Resistance…